vs
CDW Corporation（CDW）与福泰制药（VRTX）财务数据对比。点击上方公司名可切换其他公司
CDW Corporation的季度营收约是福泰制药的1.7倍（$5.5B vs $3.2B），福泰制药同比增速更快（9.5% vs 6.3%），CDW Corporation自由现金流更多（$395.9M vs $348.6M），过去两年福泰制药的营收复合增速更高（8.9% vs 6.3%）
CDW公司是美国多品牌信息技术服务提供商，服务覆盖美国、英国、加拿大三国的商业、政府、教育、医疗领域，总部位于伊利诺伊州弗农希尔斯，位列《财富》500强，2023年全年净销售额达210亿美元。
福泰制药是总部位于美国马萨诸塞州波士顿的生物制药企业，是全球首批明确采用理性药物设计策略、而非组合化学方法开发药物的生物技术公司之一。除波士顿总部外，公司还在加州圣迭戈、英国牛津郡米尔顿公园设有三处研发中心。
CDW vs VRTX — 直观对比
营收规模更大
CDW
是对方的1.7倍
$3.2B
营收增速更快
VRTX
高出3.3%
6.3%
自由现金流更多
CDW
多$47.3M
$348.6M
两年增速更快
VRTX
近两年复合增速
6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5B | $3.2B |
| 净利润 | — | $1.2B |
| 毛利率 | 22.8% | 85.4% |
| 营业利润率 | 7.8% | 37.8% |
| 净利率 | — | 37.3% |
| 营收同比 | 6.3% | 9.5% |
| 净利润同比 | — | 30.5% |
| 每股收益（稀释后） | $2.13 | $4.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDWVRTX
| Q4 25 | $5.5B | $3.2B | ||
| Q3 25 | $5.7B | $3.1B | ||
| Q2 25 | $6.0B | $3.0B | ||
| Q1 25 | $5.2B | $2.8B | ||
| Q4 24 | $5.2B | $2.9B | ||
| Q3 24 | $5.5B | $2.8B | ||
| Q2 24 | $5.4B | $2.6B | ||
| Q1 24 | $4.9B | $2.7B |
净利润CDWVRTX
| Q4 25 | — | $1.2B | ||
| Q3 25 | $291.0M | $1.1B | ||
| Q2 25 | $271.2M | $1.0B | ||
| Q1 25 | $224.9M | $646.3M | ||
| Q4 24 | — | $913.0M | ||
| Q3 24 | $316.4M | $1.0B | ||
| Q2 24 | $281.1M | $-3.6B | ||
| Q1 24 | $216.1M | $1.1B |
毛利率CDWVRTX
| Q4 25 | 22.8% | 85.4% | ||
| Q3 25 | 21.9% | 86.5% | ||
| Q2 25 | 20.8% | 86.3% | ||
| Q1 25 | 21.6% | 86.9% | ||
| Q4 24 | 22.3% | 85.5% | ||
| Q3 24 | 21.8% | 85.8% | ||
| Q2 24 | 21.8% | 85.9% | ||
| Q1 24 | 21.8% | 87.3% |
营业利润率CDWVRTX
| Q4 25 | 7.8% | 37.8% | ||
| Q3 25 | 7.7% | 38.6% | ||
| Q2 25 | 7.0% | 38.8% | ||
| Q1 25 | 7.0% | 22.7% | ||
| Q4 24 | 7.9% | 35.2% | ||
| Q3 24 | 8.7% | 40.3% | ||
| Q2 24 | 8.0% | -132.9% | ||
| Q1 24 | 6.7% | 42.4% |
净利率CDWVRTX
| Q4 25 | — | 37.3% | ||
| Q3 25 | 5.1% | 35.2% | ||
| Q2 25 | 4.5% | 34.8% | ||
| Q1 25 | 4.3% | 23.3% | ||
| Q4 24 | — | 31.4% | ||
| Q3 24 | 5.7% | 37.7% | ||
| Q2 24 | 5.2% | -135.8% | ||
| Q1 24 | 4.4% | 40.9% |
每股收益（稀释后）CDWVRTX
| Q4 25 | $2.13 | $4.64 | ||
| Q3 25 | $2.21 | $4.20 | ||
| Q2 25 | $2.05 | $3.99 | ||
| Q1 25 | $1.69 | $2.49 | ||
| Q4 24 | $1.97 | $3.62 | ||
| Q3 24 | $2.34 | $4.01 | ||
| Q2 24 | $2.07 | $-13.92 | ||
| Q1 24 | $1.59 | $4.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $618.7M | $6.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $18.7B |
| 总资产 | $16.0B | $25.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDWVRTX
| Q4 25 | $618.7M | $6.6B | ||
| Q3 25 | $452.9M | $6.3B | ||
| Q2 25 | $481.0M | $6.4B | ||
| Q1 25 | $688.1M | $6.2B | ||
| Q4 24 | $717.7M | $6.1B | ||
| Q3 24 | $1.2B | $6.5B | ||
| Q2 24 | $665.3M | $5.8B | ||
| Q1 24 | $803.8M | $10.2B |
股东权益CDWVRTX
| Q4 25 | $2.6B | $18.7B | ||
| Q3 25 | $2.5B | $17.3B | ||
| Q2 25 | $2.5B | $17.2B | ||
| Q1 25 | $2.3B | $16.5B | ||
| Q4 24 | $2.4B | $16.4B | ||
| Q3 24 | $2.3B | $15.6B | ||
| Q2 24 | $2.2B | $14.8B | ||
| Q1 24 | $2.1B | $18.5B |
总资产CDWVRTX
| Q4 25 | $16.0B | $25.6B | ||
| Q3 25 | $15.2B | $24.9B | ||
| Q2 25 | $15.3B | $24.0B | ||
| Q1 25 | $15.0B | $22.9B | ||
| Q4 24 | $14.7B | $22.5B | ||
| Q3 24 | $14.4B | $22.2B | ||
| Q2 24 | $13.6B | $20.1B | ||
| Q1 24 | $13.2B | $23.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $433.8M | $498.0M |
| 自由现金流经营现金流 - 资本支出 | $395.9M | $348.6M |
| 自由现金流率自由现金流/营收 | 7.2% | 10.9% |
| 资本支出强度资本支出/营收 | 0.7% | 4.7% |
| 现金转化率经营现金流/净利润 | — | 0.42× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $3.2B |
8季度趋势，按日历期对齐
经营现金流CDWVRTX
| Q4 25 | $433.8M | $498.0M | ||
| Q3 25 | $328.3M | $1.2B | ||
| Q2 25 | $155.9M | $1.1B | ||
| Q1 25 | $287.2M | $818.9M | ||
| Q4 24 | $345.3M | $584.6M | ||
| Q3 24 | $342.1M | $1.4B | ||
| Q2 24 | $149.9M | $-3.8B | ||
| Q1 24 | $440.0M | $1.3B |
自由现金流CDWVRTX
| Q4 25 | $395.9M | $348.6M | ||
| Q3 25 | $298.5M | $1.1B | ||
| Q2 25 | $133.4M | $927.4M | ||
| Q1 25 | $260.3M | $778.2M | ||
| Q4 24 | $316.7M | $492.0M | ||
| Q3 24 | $308.5M | $1.3B | ||
| Q2 24 | $119.0M | $-3.8B | ||
| Q1 24 | $410.5M | $1.2B |
自由现金流率CDWVRTX
| Q4 25 | 7.2% | 10.9% | ||
| Q3 25 | 5.2% | 37.0% | ||
| Q2 25 | 2.2% | 31.3% | ||
| Q1 25 | 5.0% | 28.1% | ||
| Q4 24 | 6.1% | 16.9% | ||
| Q3 24 | 5.6% | 47.0% | ||
| Q2 24 | 2.2% | -144.5% | ||
| Q1 24 | 8.4% | 46.0% |
资本支出强度CDWVRTX
| Q4 25 | 0.7% | 4.7% | ||
| Q3 25 | 0.5% | 3.3% | ||
| Q2 25 | 0.4% | 4.9% | ||
| Q1 25 | 0.5% | 1.5% | ||
| Q4 24 | 0.6% | 3.2% | ||
| Q3 24 | 0.6% | 2.4% | ||
| Q2 24 | 0.6% | 2.6% | ||
| Q1 24 | 0.6% | 2.5% |
现金转化率CDWVRTX
| Q4 25 | — | 0.42× | ||
| Q3 25 | 1.13× | 1.15× | ||
| Q2 25 | 0.57× | 1.04× | ||
| Q1 25 | 1.28× | 1.27× | ||
| Q4 24 | — | 0.64× | ||
| Q3 24 | 1.08× | 1.31× | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 2.04× | 1.19× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDW
暂无分部数据
VRTX
| TRIKAFTAKAFTRIO | $2.6B | 81% |
| ALYFTREK | $380.1M | 12% |
| Manufactured Product Other | $237.4M | 7% |
